Qiagen N.V. (QGEN) to Issue Annual Dividend of $0.35 on July 14th

Qiagen N.V. (NYSE:QGEN) announced an annual dividend on Monday, May 11th. Shareholders of record on Tuesday, July 7th will be paid a dividend of 0.35 per share on Tuesday, July 14th. This represents a yield of 104.0%. The ex-dividend date is Tuesday, July 7th. This is a 33.0% increase from Qiagen’s previous annual dividend of $0.26.

Qiagen has a payout ratio of 10.3% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Qiagen to earn $2.69 per share next year, which means the company should continue to be able to cover its $0.26 annual dividend with an expected future payout ratio of 9.7%.

Qiagen Stock Performance

Qiagen stock opened at $33.67 on Wednesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 3.31. Qiagen has a 12 month low of $32.60 and a 12 month high of $57.81. The company has a fifty day moving average price of $39.97 and a two-hundred day moving average price of $46.00. The company has a market cap of $6.94 billion, a PE ratio of 17.58, a P/E/G ratio of 3.25 and a beta of 0.64.

Qiagen (NYSE:QGEN) last issued its earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, meeting analysts’ consensus estimates of $0.54. The company had revenue of $492.32 million during the quarter, compared to the consensus estimate of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same period in the previous year, the firm posted $0.56 earnings per share. Research analysts expect that Qiagen will post 2.43 earnings per share for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.